logo
Plus   Neg
Share
Email

Roche: FDA Grants Polivy Accelerated Approval - Quick Facts

Swiss drug major Roche (RHHBY) announced Tuesday that the US Food and Drug Administration or FDA has granted accelerated approval to Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan (rituximab) or BR. The approval is for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma or DLBCL, who have received at least two prior therapies.

The approval for this indication was based on complete response rates observed in a randomised, controlled phase Ib/II GO29365 clinical trial.

The company noted that the new targeted medicine was shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen.

The US FDA granted Priority Review for the company's Biologics License Application for Polivy in February 2019.

Further, Roche announced that Peter Voser will step down as a member of the Board at the end of June.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>